HGS, one of three founding investors of Unest, has now merged with the company
Human Genetic Signatures Pty Ltd, Sydney, Australia (HGS) and Unest A/S, Odense, Denmark (Unest) has acquired the INAR intellectual property rights and activities of Unest.
The activities will be relocated to HGS's offices in Australia. The acquisition marks the beginning of a new chapter in the history of the two companies and their development.
By the merging of the two organizations, HGS is now in a position to fully exploit the synergy between the research programs and business strategies of the two companies.
Through the acquisition and aggregation of personnel, HGS will position themselves with a very strong IP and knowledge position, centred on an expert team. The two companies complement each other perfectly and together the development of ground breaking INAR Methylation diagnostics and therapeutic platforms for human diseases will be pursued in an ambitious and accelerated manner.
HGS is one of three founding investors of Unest and has been committed to supporting the development of Unest and the INAR technology from the inception the company.
The chairman of the board of HGS is the inventor of the Bisulphite Method used worldwide in DNA Methylation and HGS have Methylomics programs on the commercialisation of cancer diagnostics and disease therapeutics using its portfolio of technologies.
HGS is putting in place the therapeutic platforms that allow for the amelioration of complex human diseases, aging phenomena, drug treatment effects and adult stem cell transplantation.
Unest invented and commercialised the INAR technology, a new generation of synthetic DNA with improved and novel properties compared to both DNA and other known synthetic nucleic acids.
INAR has been applied with impressing performance in diagnostics and has great potential for the nucleic acid-based medicine of tomorrow.
With INAR, HGS is in a position to provide researchers with tools to solve demanding nucleic acid-based applications.
